# ELV Stock: Elevance Beat AND Raised Guidance — So Why Did It Fall?

Page: https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/elv-stock-elevance-beat-and-raised-guidance-so-why-did-it-fall
Text version: https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/elv-stock-elevance-beat-and-raised-guidance-so-why-did-it-fall.md
Podcast: [Charged Alpha Stock Encyclopedia](https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792)
Published: 2026-07-16T23:35:19+00:00
Episode link: https://chargedalpha.podbean.com/e/elv-stock-elevance-beat-and-raised-guidance-%e2%80%94-so-why-did-it-fall/
Audio file: https://mcdn.podbean.com/mf/web/65cxvpy42zj2de6k/audio_z.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/charged-alpha-stock-encyclopedia-7819792/episodes/elv-stock-elevance-beat-and-raised-guidance-so-why-did-it-fall
Duration seconds: 819

## Resource

Elevance Health (ELV) Q2 2026 — Elevance Health (ELV), one of the largest U.S. health insurers (~46M members, formerly Anthem), reported Q2 2026 adjusted EPS of $7.45, crushing the $6.18 estimate (helped by Carelon pharmacy) — but that was down from $8.84 a year ago, and the stock FELL. Despite the beat, it RAISED full-year adjusted EPS guidance to at least $27.00. The problem: a rising medical loss ratio (surging medical costs) has earnings falling YoY, and the market doubts the beat is sustainable. The stock (~$373, ~14x forward) is ~15% off its $436 high, off a $274 low. Here's a puzzle: Elevance Health (formerly Anthem) — a ~46-million-member health-insurance giant — just beat earnings AND raised its full-year guidance to at least $27/share, and the stock fell anyway. Why? Because underneath the beat is a rising medical loss ratio: members are using more care than the company priced for, so margins are compressing and adjusted EPS ($7.45) is down sharply from $8.84 a year ago. The beat was against a lowered bar, and the market doubts it's sustainable. It's a sector-wide storm (utilization, Medicare Advantage, Medicaid) hitting all managed care. The bull case: a scaled, essential insurer at ~14x (a cyclical trough), with a growing fee-based Carelon arm, that just raised guidance — the Street sees ~17% upside ($438 target) if costs peak. The bear case: earnings are falling and the MLR is still rising. Our owner-earnings work lands near $390 (vs $373) — modest upside if costs normalize. Our call: HOLD, 3/5 — cheap and raising guidance, but medical costs are the swing. Watch the MLR; add near the lows. Not financial advice. THE CALL: HOLD (3/5, CHEAP AND RAISING GUIDANCE, BUT MEDICAL COSTS ARE THE SWING) — base-case value ~$390 vs ~$373 today. What to watch: the medica…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/charged-alpha-stock-encyclopedia-7819792/episodes/elv-stock-elevance-beat-and-raised-guidance-so-why-did-it-fall/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/elv-stock-elevance-beat-and-raised-guidance-so-why-did-it-fall.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.